Development and evaluation of transdermal organogels containing Nicorandil
- Publication Type:
- Journal Article
- Citation:
- Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12 (3), pp. 246 - 251
- Issue Date:
- 2013-12-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| Galley proof - Kamal Paper.pdf | Submitted Version | 356.39 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
The objective of the study was to formulate a transdermal product containing Nicorandil as a model drug, because it has been first drug of choice to treat angina and hypertension. A further objective was to reduce its side effects. The transdermal product was prepared using various synthetic and natural gelling agents such as Carbopol 934p, Carbopol 974p, HPMC K15M and HPMC K100M. Various penetration enhancers were incorporated to enhance the diffusion across the rat skin. A further objective was to formulate organogels and minimize the concentration of penetration enhancer to 50% of the concentration used in gels and yet to achieve the maximum drug release. The prepared formulations were evaluated for their physical appearance, viscosity, spreadability, drug content and freeze thaw cycle. Based on in vitro studies across rat skin and human cadaver skin it was concluded that Nicrorandil transdermal organogel formulation using HPMC K100M with 2% w/w Transcutol-P shows increase in cumulative diffusion of Nicorandil amongst all other formulations. © 2013 Bentham Science Publishers.
Please use this identifier to cite or link to this item: